文献速递类风湿关节炎

多生物标志物疾病活动度评分在类风湿关节炎患者生物类似药相似性研究中的应用

Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.
PubMed 文献 · RMD Open · 2022-01-01

本探索性分析利用两项随机对照试验数据,评估多生物标志物疾病活动度(MBDA)评分支持生物类似药相似性评价的潜力。英夫利西单抗生物类似药(IFX-qbtx,N=650)与阿达木单抗生物类似药(ADL-afzb,N=597)分别对比原研药,各时间点平均MBDA评分高度可比。作者认为MBDA评分可能提供独立于关节计数主观性的客观定量相似性证据。

要点

  • 两项随机对照试验首次将MBDA评分作为生物类似药相似性的探索性评估。
  • IFX-qbtx与IFX-EU、ADL-afzb与ADL-EU在各测量时间点平均MBDA评分高度可比。
  • MBDA评分可能提供独立于关节计数或整体评估主观性的客观定量相似性证据。

核心结论

  • 这两项随机对照试验首次将MBDA评分纳入作为生物类似药相似性的探索性评估。
  • MBDA评分可能通过评估疾病活动度提供客观定量的生物类似药相似性证据,该评估独立于关节计数或患者/医生整体评估中固有的潜在主观性。

研究设计与样本

  • 探索性分析,利用两项随机对照试验数据,分别评估英夫利西单抗生物类似药(IFX-qbtx)与欧盟来源英夫利西单抗(Remicade;IFX-EU)、阿达木单抗生物类似药(ADL-afzb)与欧盟来源阿达木单抗(Humira;ADL-EU)在活动性类风湿关节炎成人患者中的相似性。
  • IFX研究纳入650例患者,按1:1随机分配至IFX-qbtx或IFX-EU(3 mg/kg静脉给药,第0、2、6周,之后每8周一次),均联用甲氨蝶呤。
  • ADL研究纳入597例患者,按1:1随机分配至ADL-afzb或ADL-EU(40 mg皮下注射,每两周一次),均联用甲氨蝶呤。
  • MBDA评分基于12种血清蛋白浓度采用Vectra疾病活动度算法计算,在基线及治疗期1(TP1)的IFX研究(第6、14、30周)和ADL研究(第6、12、26周)各时间点测量。
  • 数据以意向治疗人群描述性统计汇总,缺失数据不作填补。

主要发现

  • 基线平均(±SD)MBDA评分:IFX-qbtx组(n=236)为61.3(±12.5),IFX-EU组(n=248)为58.8(±13.2)。
  • 基线平均(±SD)MBDA评分:ADL-afzb组(n=292)为57.2(±14.44),ADL-EU组(n=293)为58.3(±15.34)。
  • 在每项研究的TP1所有测量时间点,IFX-qbtx与IFX-EU之间以及ADL-afzb与ADL-EU之间的平均MBDA评分高度可比。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This exploratory analysis investigated the potential use of the multibiomarker disease activity (MBDA) score to support biosimilarity assessments using data from two randomised controlled trials (RCTs) of biosimilar infliximab (IFX-qbtx) and biosimilar adalimumab (ADL-afzb) versus EU-sourced infliximab (Remicade; IFX-EU) and adalimumab (Humira; ADL-EU) reference products, respectively, both conducted in adult patients with active rheumatoid arthritis. METHODS: In one study, patients (N=650) were randomised 1:1 to IFX-qbtx or IFX-EU (3 mg/kg intravenous at weeks 0, 2 and 6, then every 8 weeks). In the other, patients (N=597) were randomised 1:1 to ADL-afzb or ADL-EU (40 mg subcutaneous every other week). All treatments were given with MTX. Mean values of MBDA scores were calculated at baseline (BL), based on the concentrations of 12 serum proteins using the Vectra disease activity algorithm, and at timepoints throughout treatment period 1 (TP1) of the IFX (weeks 6, 14, 30) and ADL (weeks 6, 12, 26) studies. Data were summarised using descriptive statistics for the intent-to-treat population, without imputation for missing data. RESULTS: At BL, mean (±SD) MBDA scores were 61.3 (±12.5) and 58.8 (±13.2) for IFX-qbtx (n=236) and IFX-EU (n=248), respectively, and 57.2 (±14.44) and 58.3 (±15.34) for ADL-afzb (n=292) and ADL-EU (n=293), respectively. Mean MBDA scores were highly comparable between IFX-qbtx and IFX-EU and between ADL-afzb and ADL-EU at all measured timepoints during TP1 in each study. CONCLUSIONS: These RCTs are the first to incorporate MBDA score as an exploratory assessment of biosimilarity. MBDA scores may provide objective, quantitative evidence of biosimilarity using an assessment of disease activity that is independent of the potential subjectivity inherent in joint counts, or in patient or physician global assessments. TRIAL REGISTRATION NUMBERS: NCT02222493 and NCT02480153.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kay J, Bock AE, Rehman M, et al. Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis. RMD Open. 2022. PMID: 36180101. doi:10.1136/rmdopen-2022-002423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。